Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;34(11):3091-3096.
doi: 10.1038/s41375-020-0750-z. Epub 2020 Mar 11.

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Vallari Shah #  1 , Amy L Sherborne #  1 , David C Johnson  1 , Sidra Ellis  1 , Amy Price  1 , Farzana Chowdhury  1 , Jack Kendall  1 , Matthew W Jenner  2 , Mark T Drayson  3 , Roger G Owen  4 , Walter M Gregory  5 , Gareth J Morgan  6 , Faith E Davies  6 , Gordon Cook  7 , David A Cairns  5 , Richard S Houlston  1   8 , Graham Jackson  9 , Martin F Kaiser  10 ; on behalf of NCRI Haematology Clinical Studies Group
Collaborators, Affiliations

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Vallari Shah et al. Leukemia. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

VS: Sanofi—travel support; Janssen—travel support. MTD: Abingdon Health—equity ownership, membership on board of directors. RGO Takeda—honoraria, travel support; Janssen—consultancy, travel support; Celgene Corporation—consultancy, honoraria, research funding. FED Amgen—consultancy, honoraria; AbbVie—consultancy, honoraria; Takeda—consultancy, honoraria; Janssen—consultancy, honoraria; Celgene Corporation—consultancy, honoraria. GJM: Janssen—research funding; Bristol-Myers Squibb—consultancy, honoraria; Takeda—consultancy, honoraria; Celgene Corporation—consultancy, honoraria, research funding. DAC: Celgene Corporation, Amgen, Merck Sharp and Dohme—research funding. GC: Takeda—consultancy, honoraria, research funding, speakers bureau; Glycomimetics—consultancy, honoraria; Sanofi—consultancy, honoraria, speakers bureau; Celgene Corporation—consultancy, honoraria, research funding, speakers bureau; Janssen—consultancy, honoraria, research funding, speakers bureau; Bristol-Myers Squibb—consultancy, honoraria; Amgen—consultancy, honoraria, research funding, speakers bureau. GJ Roche—consultancy, honoraria, speakers bureau; Amgen—consultancy, honoraria, speakers bureau; Janssen—consultancy, honoraria, speakers bureau; Merck Sharp and Dohme—consultancy, honoraria, speakers bureau; Celgene Corporation—consultancy, honoraria, travel support, research funding, speakers bureau; Takeda—consultancy, honoraria, travel support, research funding, speakers bureau. MFK Bristol-Myers Squibb—consultancy, travel support; Chugai—consultancy; Janssen—consultancy, honoraria; Amgen—consultancy, honoraria; Takeda—consultancy, travel support; Celgene Corporation—consultancy, honoraria, research funding. The remaining authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1. Patient outcome in context of GEP and chromosomal high-risk markers and their respective frequencies and distribution in Myeloma XI.
Kaplan–Meier plot of Myeloma XI trial patients (n = 329) in context of SKY92 risk profiling for (a) PFS, (b) OS from maintenance randomization, with survival curves for patients randomized to lenalidomide or observation plotted separately. Log-rank P values displayed. c, d Kaplan–Meier plots of molecular risk groups defined by absence of any high-risk marker, presence of a single genetic risk marker, presence of either double-hit or SKY92 high-risk or combined double-hit and SKY92 high-risk for c PFS, d OS from induction randomization. e Venn diagram of patients with tumors positive for validated genetic risk markers adverse translocations, gain(1q), del(17p), SKY92 GEP high-risk. % is relative to 188 patients with high-risk lesions, (%) relative to all patients (n = 329) in the study. Frequency represented by gray color coding, with darker gray indicating higher frequency.
See this image and copyright information in PMC

References

    1. Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 2017;7:e618. doi: 10.1038/bcj.2017.97. - DOI - PMC - PubMed
    1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046. doi: 10.1038/nrdp.2017.46. - DOI - PubMed
    1. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62. doi: 10.1182/blood-2016-01-631200. - DOI - PMC - PubMed
    1. Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32:102–10. doi: 10.1038/leu.2017.179. - DOI - PMC - PubMed
    1. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–55. doi: 10.1038/leu.2011.204. - DOI - PMC - PubMed

Publication types

Substances